DiaSorin Molecular LLC

DiaSorin Molecular LLC is a world leader in laboratory diagnostics, specializing in immunodiagnostics and molecular diagnostics. The company develops and manufactures in vitro diagnostic systems for detecting antibodies, antigens, and pathogens in biological specimens. Core product lines include the LIAISON® immunodiagnostic platform for infectious disease detection (tuberculosis, hepatitis, viral infections), Simplexa® molecular assay kits for direct pathogen detection (COVID-19, influenza, RSV, cytomegalovirus, herpes simplex virus), and the LIAISON NES® CLIA-waived rapid molecular test delivering results in approximately 15 minutes. Additional offerings include LIAISON® MeMed BV® for bacterial-viral differentiation, LIAISON® QuantiFERON®-TB Gold Plus II for TB detection, and LIAISON® BRAHMS PCT® for infection triage. The company also operates the Luminex division, providing xMAP® multiplex assay platforms and xMAP INTELLIFLEX® systems for research and clinical diagnostics, along with custom assay design and development services. DiaSorin serves clinical laboratories, hospitals, and research institutions globally. The company maintains regulatory compliance with FDA clearances and CLIA waivers for its diagnostic systems. Manufacturing and service capabilities span immunoassay automation, molecular PCR testing, and multiplex diagnostic platforms.